JIOH on LinkedIn JIOH on Facebook
  • Users Online: 486
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 12  |  Issue : 1  |  Page : 66-73

Statins improve periodontal disease–induced inflammatory changes and associated lipid peroxidation in patients with dyslipidemia: Two birds by one stone

1 Department of Oral Radiology, College of Dentistry, Asoul Al-Dean, Baghdad University, Baghdad, Iraq
2 Department of microbiology, College of Science, Baghdad university, Baghdad, Iraq
3 Department of Pharmacology and Toxicology, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq

Correspondence Address:
Prof. Hayder M Al Kuraishy
Department of Pharmacology, Toxicology, and Medicine, College of Medicine, Al-Mustansiriya University, P.O. Box 14132, Baghdad.
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jioh.jioh_194_19

Rights and Permissions

Aim: To show the potential role of statins on the inflammatory and lipid peroxidation biomarkers in patients with periodontal disease (PD). Materials and Methods: This case-controlled cross-sectional study involved 74 patients with PD and/or dyslipidemia divided into: Group (A): 34 patients with PD not on statin therapy (non-statin users), Group (B): 40 patients with PD on statin therapy (statin users), and Group (C): 30 healthy controls. Total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and malondialdehyde (MDA) were measured. Also blood pressure profile and the indices of PD were evaluated in each group. Statistical analysis was conducted by using the Statistical Package for the Social Sciences (SPSS). Results: Patients with PD showed high cardiometabolic disturbances compared with control subjects. Inflammatory and lipid peroxidation biomarkers were higher in patients with PD compared with control subjects; IL-6, CRP, TNF-α, and MDA sera level were high in patients with PD compared with control subjects (P = 0.001). Statin therapy, either simvastatin or atorvastatin, led to significant reduction in TC, TG, VLDL, LDL, blood pressure profile, and cardiac risk indices with elevation in HDL compared with non-statin user (P < 0.01). Also, statin therapy in patients with PD led to significant reduction in IL-6, CRP, TNF-α, and MDA sera levels compared with non-statin user (P < 0.05). Simvastatin and atorvastatin produced improved periodontal indices compared with non-statin user (P < 0.05). Conclusion: Both simvastatin and atorvastatin are effective therapies in patients with PD through amelioration of PD-induced inflammatory disorders and periodontal indices.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded95    
    Comments [Add]    
    Cited by others 1    

Recommend this journal